Photo of Michael A. Fifer, MD

Michael A. Fifer, MD

  • Med Dir, Knight Center for Interventional Cardiovascular Therapeutics
  • Co-director, Hypertrophic Cardiomyopathy Program


Accepting New Patients


Michael A. Fifer, MD, directs the Cardiac Cath Lab, Interventional Cardiology Associates, and the Hypertrophic Cardiomyopathy Program at the Massachusetts General Hospital Heart Center.




Centers & Specialties

Heart Center

Clinical Interests
  • Hypertrophic cardiomyopathy
  • Left ventricular hypertrophy
Medical Education
  • MD, Harvard Medical School
  • Residency, Massachusetts General Hospital
  • Fellowship, Brigham and Women's Hospital
Board Certifications
  • Cardiovascular Disease
  • Internal Medicine
  • Boston: Massachusetts General Hospital
Insurances Accepted
  • Aetna Health Inc.
  • Beech Street
  • Blue Cross Blue Shield - Blue Care 65
  • Blue Cross Blue Shield - Indemnity
  • Blue Cross Blue Shield - Managed Care
  • Blue Cross Blue Shield - Partners Plus
  • Centene/Celticare
  • Cigna (PAL #'s)
  • Fallon Community HealthCare
  • Great-West Healthcare (formally One Health Plan)
  • Harvard Pilgrim Health Plan - ACD
  • Harvard Pilgrim Health Plan - other
  • Harvard Pilgrim Health Plan - PBO
  • Health Care Value Management (HCVM)
  • Humana/Choice Care PPO
  • MassHealth
  • Medicare
  • Medicare - ACD
  • Neighborhood Health Plan - ACD
  • Neighborhood Health Plan - PBO
  • OSW - Connecticut
  • OSW - Maine
  • OSW - New Hampshire
  • OSW - Rhode Island
  • Private Health Care Systems (PHCS)
  • Railroad Medicare
  • Railroad Medicare - ACD
  • Senior Whole Health
  • TriCare
  • Tufts Health Plan
  • Unicare
  • United Healthcare (non-HMO) - ACD
  • United Healthcare (non-HMO) - PBO
Patient Age Group

Edit Profile


Dr. Fifer received his undergraduate degree summa cum laude from Harvard College and completed his medical degree at Harvard Medical School. Following internship and residency at Massachusetts General Hospital, he completed his subspecialty fellowship in cardiovascular diseases at Brigham and Women's Hospital. Dr. Fifer joined the faculty of Harvard Medical School in 1984 and is currently a Professor of Medicine in the Cardiology Division at Massachusetts General Hospital where he is Medical Director of the Knight Cardiac Catheterization Laboratory, Co-director with Dr. Gus J. Vlahakes of the Hypertrophic Cardiomyopathy Program, and Director of Interventional Cardiology Associates.  Dr. Fifer also maintains a general cardiology practice. 

Dr. Fifer's research focuses on hypertrophic cardiomyopathy.  He has been a pioneer in the use of alcohol septal ablation, an innovative procedure for patients with the obstructive form of hypertrophic cardiomyopathy. The research arm of the program is currently conducting translational and clinical studies aimed at elucidating the pathophysiologic mechanism of the disease and discovering new treatments.

Edit Profile

Research & Publications

Research Summary
Dr. Fifer's research focuses on hypertrophic cardiomyopathy.  He introduced alcohol septal ablation, an innovative procedure for patients with hypertrophic obstructive cardiomyopathy, to the northeastern United States.  He has published definitive reviews on the management of hypertrohpic cardiomyopathy in Circulation.  The research program of the Hypertrophic Cardiomyopathy Program of the Heart Center of Massachusetts General Hospital is currently conducting translational and clinical studies aimed at elucidating the pathophysiologic mechanism of hypertrophic cardiomyopathy and discovering new treatments for the disease.

View my most recent publications at PubMed

Rothman RD, Baggish AL, O?Callaghan C, Lowry PA, Bhatt AB, MacRae CA, Yannekis G, Sanborn DM, Mela T, Yeh RW, Palacios I, Vlahakes GJ, Fifer MA.  Management strategy in 249 consecutive patients with obstructive hypertrophic cardiomyopathy referred to a dedicated program.  Am J Card 2012;110:1169-74.

Elmariah S, Fifer MA.  Medical, surgical and interventional management of hypertrophic cardiomyopathy with obstruction.  Curr Treat Options Cardiovasc Med 2012;14:665-678.

Sanborn DMY, Sigwart U, Fifer MA. Patient selection for alcohol septal ablation for hypertrophic obstructive cardiomyopathy: clinical and echocardiographic evaluation. Interv Cardiol 2012;4:349-59.

Shimada YJ,. Passeri JJ, Baggish AL, O?Callaghan C, Lowry PA, Yannekis G, Abbara S, Ghoshhajra BB, Ho CY, Januzzi JL, Seidman CE, Fifer MA. Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy.  J Am Coll Cardiology HF 2013;1:480-7.

Edit Profile

News & Events

  • U.S. congressman tours MGH labs

    MGH Hotline 6.10.11 U.S. Rep. Erik Paulsen, co-chair of the Medical Technology Caucus, visited the MGH on May 18 to tour the Tissue Engineering and Organ Fabrication Laboratory in the Richard B. Simches Research Center and the Cardiac Catheterization Laboratory on Blake 9.

  • Advanced blood analysis may speed diagnosis of heart attacks

    Study of 'planned' heart attacks identifies markers that could improve treatment, save lives.


Interventional Cardiology Associates
55 Fruit Street
Boston MA, 02114
Phone: 617-726-1832
Fax: 617-726-7437

Edit Profile

Back to Top